Stocktoria
Krystal Biotech, Inc. KRYS
Krystal Biotech, Inc. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $389.1M | $290.5M | $50.7M | $0 | $0 | — | — | — | — | — |
| R&D expense | $58.0M | $53.6M | $46.4M | $42.5M | $27.9M | $17.9M | $15.6M | $7.8M | $3.2M | $741,000 |
| SG&A expense | $146.7M | $113.6M | $98.3M | $77.7M | — | — | — | — | — | — |
| Operating income | $161.3M | $65.7M | -$109.6M | -$145.2M | -$68.3M | -$33.0M | -$22.1M | -$11.9M | -$4.8M | -$1.1M |
| Interest expense | — | — | $0 | $0 | $1.5M | $0 | — | — | — | — |
| Income tax | -$15.4M | $6.2M | $2.0M | $0 | $0 | $0 | $0 | $0 | $0 | — |
| Net income | $204.8M | $89.2M | $10.9M | -$140.0M | -$69.6M | -$32.2M | -$19.1M | -$10.9M | -$7.9M | -$1.1M |
| EPS (diluted) | $6.84 | $3.00 | $0.39 | $-5.49 | $-3.13 | $-1.71 | — | — | — | — |
| Operating cash flow | $200.9M | $123.4M | -$88.8M | -$100.6M | -$47.9M | -$26.1M | -$18.7M | -$9.4M | -$3.9M | -$1.3M |
| Free cash flow | $188.9M | $119.2M | -$100.6M | -$153.5M | -$116.3M | -$40.9M | -$25.1M | -$11.7M | -$4.1M | -$1.3M |
| Cash & equivalents | $496.3M | $344.9M | $358.3M | $161.9M | $341.2M | $268.3M | $187.5M | $103.7M | $49.6M | $1.9M |
| Inventory | $40.5M | $26.5M | $7.0M | $0 | — | — | — | — | — | — |
| Total assets | $1.3B | $1.1B | $818.4M | $558.5M | $626.3M | $310.8M | $209.0M | $116.1M | $50.1M | $2.2M |
| Total liabilities | $114.2M | $109.5M | $39.7M | $36.2M | $32.7M | $18.8M | $6.1M | $2.9M | $640,000 | $1.9M |
| Shareholders' equity | $1.2B | $946.4M | $778.6M | $522.2M | $593.6M | $292.1M | $202.9M | $113.2M | $49.5M | $289,000 |
Growth · year-over-year
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +33.9% | +473.0% | — | — | — | — | — | — | — | — |
| Net income growth | +129.7% | +715.6% | — | — | — | — | — | — | — | — |
| EPS growth | +128.0% | +669.2% | — | — | — | — | — | — | — | — |
| Free cash flow growth | +58.5% | — | — | — | — | — | — | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.